Agilent Technologies, Inc. (NYSE:A) is a prominent player in the life sciences sector, known for its medical tools and equipment essential for lab research and diagnostic services. The company competes with other major firms in the industry, focusing on innovation and quality. Agilent's recent financial performance highlights its strong market position and growth potential.
On November 24, 2025, Agilent reported earnings per share (EPS) of $1.59, aligning with the estimated EPS of $1.59. This stability in earnings estimates is crucial as it often influences investor behavior and can impact the short-term price performance of the stock. The company's revenues reached approximately $1.84 billion, surpassing the estimated $1.83 billion, reflecting a 7.8% rise from the same quarter last year.
Agilent's fourth-quarter revenue of $1.86 billion exceeded its guidance, marking a 9.4% increase compared to the same period in 2024. The company's core growth was 7.2%, driven by robust demand for its products. Agilent's GAAP net income for the quarter was $434 million, or $1.53 per share, an improvement from the previous year's $351 million, or $1.22 per share.
The company's non-GAAP net income reached $452 million, or $1.59 per share, highlighting its strong financial performance. Agilent's price-to-earnings (P/E) ratio is approximately 35.88, indicating investor confidence in its earnings potential. The price-to-sales ratio stands at about 6.42, reflecting its market value relative to sales.
Agilent's financial metrics, such as the enterprise value to sales ratio of 6.69 and the enterprise value to operating cash flow ratio of 30.38, provide insight into its valuation. The earnings yield is about 2.79%, offering a perspective on return on investment. With a debt-to-equity ratio of 0.54 and a current ratio of 2.25, Agilent demonstrates a balanced financial structure and strong liquidity position.
